Pfizer Internal Medicine
CONFIDENCE is a real-world study looking at how well rimegepant orally disintegrating tablet works for the acute treatment of migraine attacks, and how satisfied people are with the treatment over time. The study examined adults who were already using rimegepant. People could also keep taking preventive migraine medicines, as long as their preventive medication dose remained stable.
Researchers focused on patient-reported outcomes, such as meaningful pain relief, ability to return to normal activities within set time windows after taking rimegepant, and overall treatment satisfaction. These outcomes were evaluated across multiple migraine attacks to understand how consistent the results were, both at the group level and for individual participants.
Overall, rimegepant showed consistent benefits across attacks. Patients reported meaningful pain relief, a return to normal function, and high satisfaction, including among those using preventive treatments. More results and supporting details are provided below.
People with migraine need acute treatments that work quickly and reliably. However, results from traditional clinical trials may not always reflect what happens when a medicine is used in routine care, including by people who are also taking preventive migraine medicines.
This study is important because CONFIDENCE provides prospective, real-world evidence on rimegepant for the acute treatment of migraine, with a focus on outcomes that matter to patients. Rather than relying on a single treated attack, it evaluates meaningful pain relief, return to normal activities, and overall satisfaction across multiple migraine attacks, helping to evaluate whether benefits are consistent over time.
Together, these findings help clinicians and patients better understand what to expect from rimegepant when used in real-world settings, including in people using stable preventive migraine treatments.
EM-GLB-RMGP-0092 | April 2026 Page published: 01-May-2026
[Sep-2025] A poster presentation from the 22nd International Headache Congress. Encored Dec-2025 at the 19th European Headache Congress
[Dec-2025] A poster presentation from the 19th European Headache Congress
A Real-world, Prospective Observational Study of Rimegepant ODT for the Acute Treatment of Migraine Attacks in Adults. (CONFIDENCE)
